2024-10-31 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**Company Overview:** Abbott Laboratories is a multinational healthcare company that develops, manufactures, and markets a wide range of healthcare products, including pharmaceuticals, medical devices, nutritionals, and diagnostics.

**Performance Analysis:**

**1. Relative Performance:**
* **Cumulative Return:** 103.03% (ABT) vs 136.74% (VOO).
* **Relative Underperformance:** -33.71% (current), with a relative performance ranking of 9.83%. This suggests that ABT has underperformed the S&P 500 over the period analyzed, but it's currently performing better than 9.83% of its historical performance range. 

**2. Recent Price Movement:**
* **Closing Price:** 113.4 (Last-market: 113.91).
* **Moving Averages:** 5-day: 115.05, 20-day: 115.55, 60-day: 113.86. 
* **Analysis:** The stock is trading below its 5-day and 20-day moving averages, suggesting a short-term downtrend. However, it is above its 60-day moving average, indicating a longer-term uptrend.

**3. Technical Indicators:**
* **RSI:** 41.07. This suggests that the stock is currently in a neutral territory, neither overbought nor oversold.
* **PPO:** -0.39. A negative PPO suggests that the stock's price is declining relative to its price 12 periods ago, indicating a short-term downtrend.
* **Delta_Previous_Relative_Divergence:** -4.38. A negative value indicates a short-term downtrend in the stock's price relative to its previous performance.
* **Expected Return:** 0.0%. The expected return of 0% suggests that ABT is not expected to outperform the S&P 500 over the long term (2 years or more) based on current conditions.

**4. Recent Earnings and Outlook:**

| Date       | EPS     | Revenue  |
| ---------- | -------- | -------- |
| 2024-07-31 | 0.74    | 10.38 B$ |
| 2024-05-02 | 0.7     | 9.96 B$ |
| 2023-11-01 | 0.82    | 10.14 B$ |
| 2023-08-03 | 0.79    | 9.98 B$ |
| 2024-07-31 | 0.79    | 9.98 B$ |

* **Analysis:** The most recent earnings report (2024-07-31) showed that ABT slightly beat analyst expectations with EPS of 0.74, while revenue matched expectations at $10.38B. This suggests the company is performing relatively well despite a challenging economic environment. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter     | Revenue  | Profit Margin |
| ----------- | -------- | -------------- |
| 2024-06-30 | $10.38B | 55.64%        |
| 2024-03-31 | $9.96B  | 55.21%        |
| 2023-12-31 | $10.24B | 55.51%        |
| 2023-09-30 | $10.14B | 54.60%        |
| 2023-06-30 | $9.98B  | 55.07%        |

**Analysis:** ABT has consistently maintained a high profit margin, ranging between 54.6% and 55.64% over the past few quarters, indicating strong profitability.

**2) Capital and Profitability:**

| Quarter     | Equity    | ROE   |
| ----------- | -------- | ----- |
| 2024-06-30 | $39.32B | 3.31% |
| 2024-03-31 | $38.81B | 3.16% |
| 2023-12-31 | $38.60B | 4.13% |
| 2023-09-30 | $37.48B | 3.83% |
| 2023-06-30 | $37.17B | 3.70% |

**Analysis:** The company maintains a strong equity position and has consistently generated a decent return on equity, indicating efficient use of its capital.

**6. News and Recent Issues:**

* **Recent Earnings News:** [Please provide the specific link to the earnings news article you're referring to. I need the article to analyze it.] 
* **Recent Market Outlook:** [Provide the specific link to the market outlook article you're referring to.]
* **Analyst Opinions and Performance Highlights:** [Provide specific links to the articles you're referencing. I need the articles to summarize analyst opinions and highlight performance.]

**7. Summary:**

ABT has shown consistent profitability and a strong financial position, indicated by its high profit margin and robust equity. While recent stock performance has been relatively weak, the company remains well-positioned in the healthcare industry and continues to deliver solid earnings. However, ABT's current underperformance against the S&P 500 suggests that investors might need to carefully evaluate its potential for outperformance in the near term. 

**Further Research:**

* **Long-term growth prospects:** Evaluate ABT's future growth potential considering its current product portfolio, R&D investments, and competitive landscape.
* **Dividends and stock buybacks:** Assess ABT's dividend policy and potential for stock buybacks as these factors could influence returns for investors.
* **Industry trends:** Analyze the future of the healthcare industry and how ABT's position within this market may evolve.

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. 
